Drug intelligence / Profile preview

Neupedix

Development stage: Approved
Lead developer: Kevelt
Modality: Small Molecules
Administration: Intravenous

Overview

Neupedix is an approved pharmaceutical product developed by AS Kevelt, containing the active ingredient alprostadil (prostaglandin E1). It is specifically indicated for neonates with congenital heart defects that result in cyanosis, where maintaining the patency of the ductus arteriosus is vital for survival. Alprostadil acts as a potent vasodilator by binding to prostaglandin E receptors on the smooth muscle of the ductus arteriosus, preventing its closure and ensuring a temporary bypass for blood oxygenation until surgical intervention can occur. This treatment is critical for stabilizing newborns until corrective or palliative surgery can be performed.

Brand names: Neupedix
Other names: Neupedix-Keveltalprostadilprostaglandin E1PGE1PGE-1PGE 1

Targets

PDE3A (Phosphodiesterase 3A)

Beyond the preview

Go deeper on Neupedix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neupedix.

Explore the full profile